HG

HGZDY

Hangzhou Diagens Biotechnology Co., Ltd.

OTC· CIK 0002128813

—

Price

Daily candles with volume.

Catalysts

Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.

Recent

T-90d Trial Readout: TLL-018 (Phase 3)

Trial: A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd…

Results Pending: MC2-01 cream (Phase 3) — Completed 67d ago

Trial: A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects…

T-90d Trial Readout: TLL-018 (Phase 3)

Trial: A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd…

T-90d Trial Readout: TLL-018 (Phase 3)

Trial: A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd…

T-90d Trial Readout: TLL-018 (Phase 3)

Trial: A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd…

Recent activity

The latest filings, insider trades, analyst actions, press and options flow — newest first.

Oct 19, 2026 Clinical trial readout

T-90d Trial Readout: TLL-018 (Phase 3)

Trial: A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis Sponsor